



Offer Price of € 10.25 per share
Market capitalisation of Arseus amounts to € 320 million
The Offering was approximately 2 times oversubscribed

Waregem (Belgium), October 4, 2007 – Arseus NV, the former professional healthcare division of Omega Pharma, has successfully completed its initial public offering (IPO). The Shares, VVPR strips and Offering Warrants will be listed as of tomorrow, October 5, 2007, on Eurolist by Euronext Brussels. The Shares will also be traded on Eurolist by Euronext Amsterdam.

Results of the Offering

- The Offer Price amounts to €10.25 per share and applies to all investors, both in the Open Tranche and the Priority Tranche.
- Pursuant to the Offering, Omega Pharma sold 17,500,000 existing shares, increased by 2,968,144 shares through the Over-allotment Option. Additionally, Arseus has issued 6,000,000 new shares in the Offering. After the Offering, Omega Pharma holds 4,531,856 shares, assuming the full exercise of the Over-allotment Option. Additionally, 195,121 shares will be issued as a result of the Contribution in Kind of an outstanding liability for €2 million. This brings the total of outstanding Arseus shares to 31,195,121. At the Offer Price of € 10.25 per share, Arseus's market capitalisation would amount to 319.7 million.

The table below illustrates Arseus's shareholders after the Offering, before and after the exercise of the Over-allotment Option based on the Offer Price:

Shareholders	Before the Offering	%	After the Offering and the Contribution in Kind	%	After the Offering and exercise of the Over-allotment Option	%
Omega Pharma NV ⁽¹⁾	25,000,000	100	7,500,000	24.0	4,531,856	14.5
Couckinvest NV	0	0	3,712,373	11.9	3,712,373	11.9
Public	0	0	19,787,627	63.4	22,755,771	72.9
Contributors	0	0	195,121	0.6	195,121	0.6
Total	25,000,000	100	31,195,121	100.0	31,195,121	100.0

(1) Including 1 share that is held by Omega Pharma Holding (Nederland) BV.

- An over-allotment option has been granted by the selling shareholder to purchase 2,968,144 existing shares at the Offer Price. The option is exercisable as of the first listing date until 30 days thereafter. All shares covered by the Over-allotment Option are existing shares lent by the selling shareholder, Omega Pharma, to the stabilisation manager. The over-allotment shares are not accompanied by a separate VVPR strip.

- Furthermore, 3,650,575 Offering Warrants and 1,500,000 personnel warrants will be outstanding after the IPO that could each lead to the issue of one Arseus share.

Proceeds of the Offering

- The total proceeds of the Offering amount to €271.3 million.
- The gross proceeds to Arseus resulting from the sale of new shares amounts to €61.5 million.
- De sale of existing shares leads to €179.4 million gross proceeds to Omega Pharma. In case the Over-allotment Option will be fully exercised, the gross proceeds to Omega Pharma could increase to € 209.8 million.

Priority Tranche and Open Tranche

- The Priority Tranche was subscribed for 56%, which corresponds to a total number of 7,301,150 shares. As specified in the Prospectus, investors in the Priority Tranche will be fully allocated. Further, 3,650,575 Offering Warrants have been granted to existing Omega Pharma shareholders that subscribed to the Priority Tranche. 5,800,249 Priority Shares have been transferred to the Open Tranche.
- As a result of the transfer of non-subscribed Priority Shares, the number of Shares in the Open Tranche increased to a total of 16,198,850. The enlarged Open Tranche was two times oversubscribed.
- The portion of the Offering that was reserved for retail investors in the enlarged Open Tranche, was oversubscribed 1.6 times, while the portion of the Offering reserved for institutional investors in the enlarged Open Tranche, was oversubscribed 2.2 times. As a result of this oversubscription, the orders from retail investors in the Open Tranche will be reduced as follows:

Number of shares requested per order	Allocation percentage	
	Orders submitted with the syndicate members	Orders submitted with other financial institutions
Up to 100	100%	100%
Between 101 and 1000	75%	60%
>1000	60%	50%

18.3% of the Shares Offered are allocated to retail investors

- 81.7% of the allocated shares (including the shares covered by the Over-allotment Option) are allotted to institutional investors in Belgium and elsewhere in the European Economic Area and Switzerland based on Regulation S of the US Securities Act of 1933.
- 18.3% of the total allocated shares¹, or 3.5 million shares, are allocated to retail investors in Belgium. Since the number of allocated shares to retail investors exceeds the number of available new shares, 85% of the shares allocated to these investors will be new shares, while 15% of the shares allocated to these investors will be existing shares. On the existing shares, a stock exchange tax of 0.17% is due with a limit of €500 per order. New shares are accompanied by VVPR strips and are not subject to any taxes.

- The Shares, VVPR strips and Offering Warrants will be listed and traded on Eurolist by Euronext Brussels and the Shares will also be traded on Eurolist by Euronext Amsterdam as of October 5, 2007 on an “as if-and-when-issued-and/or-delivered” basis under the symbols RCUS (Shares in Brussels), RCUSA (Shares in Amsterdam), RCUSS (VVPR strips) and RCUSW (Offering Warrants). Delivery and payment of the Shares is scheduled on October 9, 2007. Upon closing of the Offering, the Shares will be listed unconditionally on Eurolist by Euronext Brussels and Amsterdam on October 9, 2007.

Arseus profile

Arseus generated a turnover of € 277 million in 2006, with 1,230 staff members. Arseus supplies healthcare professionals, on a European level, with products and services that enable them to provide high-quality services in an efficient manner. Arseus services pharmacists, general practitioners, specialist physicians, dentists, eye care professionals, nursing staff as well as hospitals and elderly care homes. Ageing population and the growing consumer awareness for health, well-being and aesthetics lead to a strong growth market for Arseus.

Enquiries:

Arseus

Ger van Jeveren, Chief Executive Officer

Tel: +32 56 62 88 00

Jan Peeters, Chief Financial Officer

Omega Pharma

Chris Van Raemdonck

Tel: +32 9 381 03 31

The Offering and the distribution of the Prospectus and this press release may be restricted by law in certain jurisdictions outside Belgium. Arseus does not represent that the Prospectus or this press release may be lawfully distributed in jurisdictions outside Belgium or that the Shares, VVPR strips or Offering Warrants may be lawfully offered in compliance with any applicable registration or other requirements in jurisdictions outside Belgium, or pursuant to any exemption available thereunder. Arseus does not assume any responsibility for such distribution or offering. Accordingly, the Shares, VVPR Strips or Offering Warrants may not be offered or sold, directly or indirectly, and neither the Prospectus, this press release nor any advertising or other offering materials may be distributed or published in any jurisdiction outside Belgium, except in circumstances that will result in compliance with any applicable laws and regulations. The Prospectus does not constitute an offer to sell or a solicitation of an offer to buy any of the securities to any person in any jurisdiction in which it is unlawful to make such offer or solicitation to such person. Persons in whose possession the Prospectus or any of the securities come, must inform themselves about, and observe any such restrictions.

The Offered Shares have not been and will not be registered under the Securities Act of the USA. Subject to certain exceptions, the securities may not be offered, sold or delivered in the United States of America (USA), or to, for the account or benefit of, US persons, except in certain transactions exempt from the registration requirements of the Securities Act. The terms used in this paragraph have the meanings given to them by Regulation S. The Shares, VVPR Strips and Offering Warrants have not been approved or disapproved by the USA Securities and Exchange Commission, any state securities commission in the USA or any other USA regulatory authority, nor have any of the foregoing authorities passed upon or endorsed the merits of the securities or the accuracy or adequacy of the Prospectus. Any representation to the contrary is a criminal offence in the USA.